Did you know?

ChinaBio^® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

Free Report

State of China Life Science 2022

Free Content

Week in Review

In My Opinion

Free Articles

Subscriber Content

China Medical System Pays $11 Million for 77% Stake in UK's Midatech

publication date: Jan 29, 2019

China Medical System, a Shenzhen company that makes and distributes drugs in China, offered $11 million for a 77% stake in Midatech Pharma of the UK. Midatech is a drug delivery company. CMS will have China rights to two Midatech candidates, MTD201 and MTX110, along with rights to any other drugs it develops in the next three years. As part of the agreement, CMS will agree to not pursue a hostile Midatech takeover. Midatech shareholders must approve the share sale. More details....

Stock Symbol: (HK: 0867) (LON: MTPH)

Share this with colleagues:

This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Click here to join.